Whilst WT1 over-expression and null mutations have both been documented in cancer, implicating its dual properties as a proto-oncogene and tumor suppressor (Algar et al., 1996; Yamagami et al., 1996; Inoue et al., 1998; Menke and Van Der Eb, 1998; Tsuboi et al., 1999; Loeb and Sukumar, 2002; Li et al., 2003; Tatsumi et al., 2008), recent evidence has begun to demystify potential epigenetic regulatory functions of this protein in malignant neoplasms (Akpa et al., 2015). The gene discussed is WT1; the disease is cancer.